Orgenesis Inc. Announces $9.2M Private Placement

Company"), a leading cell and gene therapy enabling company providing centralized CDMO manufacturing and development services through its subsidiary MTH Global, Inc., as well as localized point-of-care development

Benzinga · 01/21/2020 12:04

Company"), a leading cell and gene therapy enabling company providing centralized CDMO manufacturing and development services through its subsidiary MTH Global, Inc., as well as localized point-of-care development and processing centers, announced today that it has entered into a definitive securities purchase agreement with certain institutional investors, including The Phoenix Insurance Company Ltd. and Sphera Global Healthcare Master Fund, for the sale of 2,200,000 shares of the Company's common stock in a private placement at a purchase price of $4.20 per share and warrants to purchase up to 1,000,000 shares of common stock at an exercise price of $5.50 per share. The warrants are not exercisable until after six months and expire three years from the date of issuance. The Company expects to receive gross proceeds of approximately $9,240,000 before deducting related offering expenses. The Company intends to use the proceeds of this financing to expand its point-of-care (POCare) cell-therapy platform, which is designed to collect, process and supply therapeutic cells within the patient care setting for various treatments, as well as for general corporate purposes. The offering is expected to close on or about January 23, 2020, subject to customary closing conditions.